Targeting the NAD+ Salvage Pathway: Synergistic Therapeutic Strategy for ER+ Metastatic Breast Cancer

Rebecca B Riggins; Suman Ranjit

doi:10.1210/endocr/bqad140

Targeting the NAD+ Salvage Pathway: Synergistic Therapeutic Strategy for ER+ Metastatic Breast Cancer

Endocrinology. 2023 Sep 23;164(11):bqad140. doi: 10.1210/endocr/bqad140.

Authors

Rebecca B Riggins¹, Suman Ranjit²

Affiliations

¹ Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
² Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC 20057, USA.

PMID: 37738166
DOI: 10.1210/endocr/bqad140

No abstract available

Keywords: ESR1 mutant metastatic breast cancer; fluorescence lifetime imaging microscopy; fulvestrant; metabolic reprogramming; nicotinamide phosphoribosyltransferase.

Publication types

Editorial
Research Support, N.I.H., Extramural
Comment

MeSH terms

Breast / metabolism
Breast Neoplasms* / metabolism
Female
Humans
NAD / metabolism
Nicotinamide Phosphoribosyltransferase / metabolism

Substances

NAD
Nicotinamide Phosphoribosyltransferase

Grants and funding

P30 CA051008/CA/NCI NIH HHS/United States